人福医药：左炔诺孕酮片获得药品注册证书

Core Insights - The company announced that its subsidiary, Wuhan Jiulong Renfu Pharmaceutical Co., Ltd., received the drug registration certificate for Levonorgestrel Tablets from the National Medical Products Administration [1] - Levonorgestrel Tablets are indicated for emergency contraception in women, with an estimated national sales revenue of approximately 1.14 billion yuan for the year 2024 [1] - The company invested around 13.5 million yuan in the research and development of this product, with the application submitted in May 2024 [1]